Because of the risk of producing hyperkalaemia, spironolactone should be given with caution to patients with impaired renal function. It should be given under careful supervision in patients with severe hepatic disease as stupor and transient hepatic coma may develop in these patients. Spironolactone may enhance the effects of other antihypertensive agents, the dose of which may need to be reduced. Serum electrolytes should be estimated periodically. The symptoms of overdosage are hyperkalaemia clinically characterised by paralysis, or muscle spasm.
Treatment is symptomatic with emphasis on potassium excretion.
While biconvex tablet.